Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/8/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Lloyd H. Kasper

Wrong Dr. Lloyd H. Kasper?

Professor of Medicine, Microbiolo...

Local Address:  New Hampshire , United States
Geisel School of Medicine at Dartmouth College

Employment History

  • Immunologist and Neurologist
    Geisel School of Medicine at Dartmouth College
  • Director of the Multiple Sclerosis Center
  • Neurologist
  • Dartmouth College
  • Medical Director
  • Director of the Multiple Sclerosis Center

Board Memberships and Affiliations


  • M.D.
  • M.D
41 Total References
Web References
Lloyd Kasper, ..., 8 Aug 2015 [cached]
Lloyd Kasper, M.D.
Lloyd Kasper, M.D.,
Professor of Medicine, Microbiology and Immunology, Geisel School of Medicine at Dartmouth College
Dr. Lloyd Kasper has been actively involved for many years in basic and applied neuroimmunology supported by research grants from the National Institutes of Health, March of Dimes, National Multiple Sclerosis Society and industry. He has published extensively on the immunology of the obligate intracellular parasite, Toxoplasma gondii, having identified critical antigens and immune pathways that are involved in disease pathogenesis. Some of these parasite antigens have been patented and extensively utilized by industry to develop neonatal screening for toxoplasma infection in the US and Europe. He established and was the long-time Director of the Dartmouth MS Center that serves an MS population of >1500 patients in northern New England. His basic research interests in MS are related primarily to understanding disease pathogenesis, the role of specific regulatory populations elicited by current and novel therapies, and the role of the gut microbiome in the regulation of CNS demyelination.
The National Multiple Sclerosis Society (NMSS), NIH and industry have awarded multiple grants to him to support this work. Dr. Kasper has been PI and co-investigator for NIH supported clinical trials in MS including anti-CD40L (CD154), CombiRx, estriol plus glatiramer and CTLA4-Ig. He has served as an advisor for industry (Biogen Idec, Novartis, Genzyme, Sanofi, Teva Neuroscience, Mederex, Centocor, Bayer Healthcare, EMD Serono, ONO Pharmaceuticals, Genentech) on clinical and research protocol development for a number of clinical trials in MS including rituximab, ocrilizumab, alumtuzumab, daclizumab, ONO-4641, anti-IL12p40, lacquinimod, anti-CD40, CTLA-4Ig, TACI-Ig, and FTY-720. He has served in ad hoc, permanent and chairperson positions on NIH and NMSS study section. He has organized three Keystone symposia including Opportunistic Infections in AIDS, Translational Medicine in Autoimmunity and most recently the Role of the Gut Microbiome: Effector/Regulatory Networks that was held in February 2013. Dr. Kasper has authored over 175 research and clinical articles related to his basic research interests in immunology and clinical expertise in multiple sclerosis.
The study adds more evidence that ... [cached]
The study adds more evidence that "bacteria have the capacity in and of themselves to modulate the immune system and make it respond in a positive way," said Lloyd Kasper, M.D., an immunologist and neurologist at Geisel School of Medicine at Dartmouth College in New Hampshire, who was not involved in the study.
The experiments did not use an MS model, but in an interview with the MS Discovery Forum (MSDF), Kasper speculated that the bacteria metabolites might have a similar effect in mouse models of MS. Three years ago, Kasper's team reported that a molecule on the surface of one common species of gut bacteria (Bacteroides fragilis) protected against central nervous system demyelinating disease in two experimental autoimmune encephalomyelitis mouse models, apparently by turning on Tregs, both prophylactically and therapeutically (Ochoa-Repáraz, et al., 2010).
Similar caveats apply to all work on how the microbiome affects immune function, Kasper and Mazmanian said.
Symbiotix' lead clinical ..., 1 June 2015 [cached]
Symbiotix' lead clinical candidate, Polysaccharide A (PSA), is the first molecule to emerge from the microbiome and the $2.3 million NIH award enables the completion of key translational studies and production of material needed to take into human clinical trials as a novel treatment for multiple sclerosis (MS), said Prof. Lloyd Kasper, Professor of Medicine, Microbiology and Immunology at Geisel School of Medicine at Dartmouth College, and Co-Founder of Symbiotix.
PSA is a first-in-class oral therapy that works through a novel mechanism of action related to activation of regulatory T cells, which exert an anti-inflammatory effect through the production of IL-10.
"Current FDA-approved therapies for multiple sclerosis offer only partial benefit for reduction of relapses and time to disability. However, all of these FDA-approved treatments have side effects some of which can be rather profound," said Prof. Kasper. "We are developing PSA as a safe and effective new oral therapy for the over 500,000 US patients with multiple sclerosis.
Lloyd Kasper, M.D. - Founder ..., 8 Aug 2015 [cached]
Lloyd Kasper, M.D. - Founder and Director Professor of Medicine, Microbiology and Immunology, Geisel School of Medicine at Dartmouth College
Newswise, 10 Feb 2005 [cached]
The Center will be directed by Randolph J. Noelle, Ph.D, with Lloyd Kasper, M.D serving as Co-Director.
In addition to being an accomplished immunologist who studies the immune response to parasitic diseases, Center Co-Director Lloyd Kasper, M.D. is a neurologist and the Director of the Multiple Sclerosis Center at Dartmouth.A significant component of Dr. Kasper's clinical practice is to bring to the forefront, the use of novel immunotherapeutics for the treatment of MS. His work in this area has brought Dartmouth both national and international recognition as a site where pivotal clinical trials in MS are done.
Other People with the name "Kasper":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.